Table 1.
Synthesis of the results and network quality assessment.
| Outcome | Measure | Model type | Pirfenidone vs Placebo, estimate (95% CI) | Nintedanib vs Placebo, estimate (95% CI) | Pirfenidone vs Nintedanib, estimate (95% CI) | Mean residual deviance |
|---|---|---|---|---|---|---|
| Decline in percent predicted FVC ≥ 10% | OR | Random effect | 0.54 (0.37–0.80) I2 = 53% |
0.59 (0.41–0.84) I2 = 48% |
0.91 (0.45–2.03) | 12.17 |
| Low quality (⊕⊕OO)a,b | ||||||
| Acute exacerbations | OR | Random effect | 0.77 (0.26–2.28) | 0.61 (0.20–1.90) I2 = 77% |
0.39 (0.00–15.53) | 11.57 |
| (⊕⊕OO)a,b | ||||||
| Mortality | OR | Random effect | 0.68 (0.46–1.03) I2 = 0% |
0.70 (0.45–1.09) I2 = 0% |
0.93 (0.38–1.94) | 14.76 |
| (⊕⊕OO)b,c | ||||||
| Dropouts | OR | Random effect | 1.27 (0.96–1.68) I2 = 0% |
1.61 (1.13–2.28) I2 = 17% |
0.75 (0.33–1.27) | 24.11 |
| Low quality (⊕⊕OO)a,b | ||||||
| Serious adverse events | OR | Random effect | 1.00 (0.78–1.29) I2 = 0% |
0.99 (0.78–1.28) I2 = 0% |
1.02 (0.62–1.62) | 11.51 |
| Moderate quality (⊕⊕⊕O)b |
a
Inconsistency;
b
Imprecision;
c
Poor quality of direct evidence.
⊕ indicator of quality; high (4/4) ,moderate (3/4) ,low (2/4) ,very low (1/4)